Repurposing the HCV NS3–4A protease drug boceprevir as COVID-19 therapeutics. Rick Oerlemans, Angel Jonathan Ruiz-Moreno, Yingying Cong, Nilima Dinesh Kumar, Marco A. Velasco-Velazquez, Constantinos G. Neochoritis, Jolanda Smith, Fulvio Reggiori, Matthew R. Groves, Alexander Dömling
, RSC Med. Chem.
, 2021
, 12
, 370
New developments in RiPP discovery, enzymology and engineering. Manuel Montalbán-López, Thomas A. Scott, Sangeetha Ramesh, Imran R. Rahman, Auke J. van Heel, Jakob H. Viel, Vahe Bandarian, Elke Dittmann, Olga Genilloud, Yuki Goto, María José Grande Burgos, Colin Hill, Seokhee Kim, Jesko Koehnke, John A. Latham, A. James Link, Beatriz Martínez, Satish K. Nair, Yvain Nicolet, Sylvie Rebuffat, Hans-Georg Sahl, Dipti Sareen, Eric W. Schmidt, Lutz Schmitt, Konstantin Severinov, Roderich D. Süssmuth, Andrew W. Truman, Huan Wang, Jing-Ke Weng, Gilles P. van Wezel, Qi Zhang, Jin Zhong, Jörn Piel, Douglas A. Mitchell, Oscar P. Kuipers, Wilfred A. van der Donk
, Nat. Prod. Rep.
, 2021
, 38
, 130
Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors. Tika R. Malla, Anthony Tumber, Tobias John, Lennart Brewitz, Claire Strain-Damerell, C David Owen, Petra Lukacik, H. T. Henry Chan, Pratheesh Maheswaran, Eidarus Salah, Fernanda Duarte, Haitao Yang, Zihe Rao, Martin A. Walsh, Christopher J. Schofield
, Chem. Commun.
, 2021
, 57
, 1430